Latest Headlines
CATEGORY
-
2023-09-18Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023On September 14, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") was the recipient of the prestigious "Most Promising Cell Therapy Pipeline in APAC" award at the 7th Annual Cell & Gene Therapy World Asia 2023, amidst a pool of international biotechnology companies.READ MORE -
2023-09-11Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid TumorsOn September 9th, 2023, Biosyngen Pte Ltd (hereafter as “Biosyngen”) announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and other advanced solid tumors. The approval granted toREAD MORE -
2023-06-05Biosyngen’s Cell Therapy BRG01 Granted Orphan Drug Designation by the U.S. FDA for Treatment of Nasopharyngeal CancerJun. 1st, 2023, Biosyngen Pte. Ltd. (hereinafter as “Biosyngen”) announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) has granted to its application, for immune cell therapy BRG01for the treatment of nasopharyngeal cancer, the status of Orphan DruREAD MORE -
2023-04-19Biosyngen announces FDA IND approval of its second product for EBV-positive lymphomaApril 15, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment of EBV-positive lymphoma. A week prior to this, the IND application of the same therapy has just beenREAD MORE -
2023-04-11Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive LymphomaApril 7th, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) was granted IND approval by China NMPA for the company’s first-in-class T-cell redirection therapy, it is an autologous T cell therapy for EBV-positive lymphoma. The principle of autologous T cell therapy is to genetically modify patienREAD MORE -
2023-03-29PM Lee receives a first-hand update by Biosyngen on its progress in cell therapyThe city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, Health Minister Ong Ye Kung, Senior Minister of State for ForeREAD MORE
